A more joined-up approach to procurement criteria is needed in Europe for the biosimilars industry to remain sustainable at a time of rising costs and downwards pressure on pricing, heard attendees at Medicines for Europe’s 18th Biosimilar Medicines Conference in Brussels, Belgium, in early October.
With a major shake-up of EU pharma legislation on the horizon, the European Commission “is looking very carefully at procurement,”...






